Related News for BIOCON

Nifty rides with bulls, can hit 24,600: Analysts

 01 Jul 05:50 AM

Stocks expected to show bullishness include Reliance, ICICI Bank, LIC Housing Finance, Grasim, Praj Industries, Biocon, Apollo Tyres, Tata Motors, and BEL. Consider a moderately bullish strategy using a Bull-Call Spread for the July 4 weekly expiry.

BIOCON: CO IN INVESTOR PRESENTATION SAYS - FY25 GUIDANCE REVENUE GROWTH IN HIGH SINGLE DIGITS TO LOW DOUBLE DIGITS; OPERATING EBITDA MARGINS COMPARABLE TO FY24; SINGLE DIGIT PAT GROWTH || BIOSIMILARS ARE AN ATTRACTIVE MARKET WITH THE GLOBAL BIOSIMILAR MARKET EXPECTED TO REACH $56B BY 2030

 27 Jun 07:15 PM

BIOCON: CO IN INVESTOR PRESENTATION SAYS - FY25 GUIDANCE REVENUE GROWTH IN HIGH SINGLE DIGITS TO LOW DOUBLE DIGITS; OPERATING EBITDA MARGINS COMPARABLE TO FY24; SINGLE DIGIT PAT GROWTH || BIOSIMILARS ARE AN ATTRACTIVE MARKET WITH THE GLOBAL BIOSIMILAR MARKET EXPECTED TO REACH $56B BY 2030

F&O stocks to buy today: ICICI Bank, Biocon among top 6 trading ideas for 27 June 2024

 27 Jun 09:42 AM

Experts suggest buying opportunities in stocks like Indus Tower, ICICI Bank, Grasim Industries, and Kotak Mahindra Bank for short-term traders, as per recommendations on ETNow.

Excited about gain in market share in US, says Biocon chief Kiran Mazumdar Shaw

 25 Jun 05:44 PM

Biocon Executive Chairperson Kiran Mazumdar Shaw say we've seen significant market share growth for our biosimilars in the US, exceeding our 20% global insulin market target sooner than expected. Demand has surged, especially for insulins, creating substantial opportunities.

Biocon Biologics gets EMA nod to produce biosimilar Bevacizumab at Bengaluru plant

 24 Jun 11:38 AM

Biocon Biologics received EMA approval to manufacture biosimilar Bevacizumab in Bengaluru, providing additional capacity to address patients' needs in Europe for treating cancer. The Bengaluru facility was also approved for biosimilar Trastuzumab manufacturing. EMA renewed GMP certificates for Biocon's facilities in Bengaluru and Malaysia. USFDA issued four observations after inspecting Biocon's Andhra Pradesh plant, concluding inspections on June 21, 2024.

BIOCON: EMA APPROVES BIOCON BIOLOGICS’ NEW MABS FACILITY IN INDIA AND RENEWS GMP CERTIFICATIONS FOR INDIA AND MALAYSIA SITES

 24 Jun 08:12 AM

BIOCON: EMA APPROVES BIOCON BIOLOGICS’ NEW MABS FACILITY IN INDIA AND RENEWS GMP CERTIFICATIONS FOR INDIA AND MALAYSIA SITES

Biocon gets 4 observations from USFDA for Andhra Pradesh facility

 22 Jun 07:22 PM

Biocon received four observations from the US health regulator after a GMP inspection at its API facility in Andhra Pradesh.

BIOCON: CO SAYS USFDA CONCLUDES INSPECTION WITH FOUR OBSERVATIONS AT API FACILITY IN VISAKHAPATNAM

 22 Jun 06:07 PM

BIOCON: CO SAYS USFDA CONCLUDES INSPECTION WITH FOUR OBSERVATIONS AT API FACILITY IN VISAKHAPATNAM

Biocon seeks partner to test generic Wegovy, Ozempic in China

 20 Jun 03:57 PM

India's Biocon is seeking a Chinese partner to conduct clinical trials on generic versions of Novo Nordisk's popular diabetes drug Ozempic and weight loss treatment Wegovy. Biocon aims to eventually launch these generics globally, with plans to find a partner for the trials on over 500 patients in China, citing the substantial investment required. The move comes ahead of the patent protection expiry on key ingredients in the drugs in 2026.

Biocon, ABB India among 5 stocks with short buildup

 18 Jun 11:20 AM

In Tuesday's trading session, five stocks saw increased open interest and trading volumes despite falling prices, indicating a short buildup as investors anticipate further declines, prompting fresh short positions in the Futures and Options segment.